drugset / Trial / NCT03038646

A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects

NCT03038646

Phase 1 Completed 14 enrolled Minerva Neurosciences
RandomizedCrossoverOpen-labelOther

Summary

* To evaluate the pharmacokinetic (PK) profiles of MIN-l0l following administration of modified release (MR) formulations of MIN-l0l in healthy male and female subjects * To select 1 MR formulation for use in fed state * To evaluate the effect of food on the bioavailability of MIN-l0l selected MR formulation

Timeline

Start
2016-11-30
Primary completion
2017-04-20
Completion
2017-04-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Roluperidone Small molecule 32 mg

Indications

No indication recorded.